Novogaia

Novogaia is a biotech company pioneering AI-enabled drug discovery from fungi. The company develops small-molecule medicines by rapidly characterizing new fungal chemical space and mapping it to biologically and commercially de-risked drug targets in areas of unmet medical need, starting with autoimmune disease. Novogaia's core technology integrates machine learning, fungal genomics, and mass spectrometry to overcome the bottleneck of natural product discovery at scale. Its flagship model, Gaia-01, is a 1-billion-parameter autoregressive transformer that predicts full molecular structures directly from mass spectrometry data, outperforming all current state-of-the-art models with a 13% accuracy improvement on the MassSpecGym benchmark. The company was founded in 2024 by CEO Tess Bevers and is backed by BACKED VC. Novogaia has offices in San Francisco and London and a team of 6.